MedPath

Predictive factors associated with virological response in Ombitasvir/Paritaprevir/Ritonavir/Ribavirin combination therapy for genotype2a infected chronic hepatitis C patients

Not Applicable
Conditions
Chronic hepatitis C
Registration Number
JPRN-UMIN000026640
Lead Sponsor
ipppon Medical School Chiba Hokusoh Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
98
Inclusion Criteria

Not provided

Exclusion Criteria

1History of allergy to Ombitasvir/Paritaprevir /Ritonavir/Ribavirin 2Liver cirrhosis 3Patients with creatinine clearance less than 50 ml / min 4Pregnant woman or lactating mother 5Hepatocellular carcinoma, or other malignant tumor 6Judged by investigator not to be appropriate for inclusion in this study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath